menu
    • menu

    Company profile for Sagimet Biosciences

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are focused on blocking fatty acid synthase (FASN) a key regulator of lipid synthesis, FASN activity is increased in certain diseases such as in the liver of patients with NASH and in certain tumor types. We believe that FASN provides an intervention point for clinical benefit. Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN in clinical developme...
    We are focused on blocking fatty acid synthase (FASN) a key regulator of lipid synthesis, FASN activity is increased in certain diseases such as in the liver of patients with NASH and in certain tumor types. We believe that FASN provides an intervention point for clinical benefit. Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN in clinical development. Phase 1 clinical studies showed that TVB-2640 inhibits de novo lipogenesis in cancer patients and reduces liver fat synthesis in people with characteristics of metabolic syndrome.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sagimet BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    155 Bovet Road, Suite 303 San Mateo, CA 94402
    Telephone
    Telephone
    +1 650.561.8600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sagimet.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TAPI and Sagimet Biosciences Announce Global License Agreement
    TAPI and Sagimet Biosciences Announce Global License Agreement

    19 Dec 2025

    // PRESS RELEASE

    https://tapi.com/knowledge-center/tapi-and-sagimet-biosciences-announce-global-license-agreement-for-innovative-forms-of-resmetirom-api-for-sagimets-fixed-dose-combination-program/

    PRESS RELEASE
    19 Dec 2025
    Share Share
    Sagimet Biosciences Reports Positive Phase 1 Results in PK Trial
    Sagimet Biosciences Reports Positive Phase 1 Results in PK Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207571/0/en/Sagimet-Biosciences-Announces-Positive-Results-from-the-Phase-1-PK-Clinical-Trial-of-Denifanstat-and-Resmetirom-Combination.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203051/0/en/Sagimet-s-License-Partner-Ascletis-Announced-Acceptance-of-New-Drug-Application-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-by-China-s-National-Medical-Products-Ad.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Sagimet Biosciences Announces Grants Under Nasdaq Rule 5635(c)(4)
    Sagimet Biosciences Announces Grants Under Nasdaq Rule 5635(c)(4)

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202776/0/en/Sagimet-Biosciences-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Sagimet Biosciences to Participate in 8th Evercore ISI Conference
    Sagimet Biosciences to Participate in 8th Evercore ISI Conference

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3191757/0/en/Sagimet-Biosciences-to-Participate-in-the-8th-Annual-Evercore-ISI-Healthcare-Conference.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Sagimet Biosciences Reveals Q3 2025 Financials And Corporate News
    Sagimet Biosciences Reveals Q3 2025 Financials And Corporate News

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187191/0/en/Sagimet-Biosciences-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search